Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Recruiting · NCT07487883 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.
Who can take part
Inclusion criteria
- Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1;
- Availability of complete clinical and imaging data;
- Life expectancy ≥ 12 weeks;
- Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹/L or neutrophils ≥ 1.5 × 10⁹/L, PLT ≥ 100 × 10⁹/L, Hb ≥ 90 g/L; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT/AST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN;
- Patients who have not received radiotherapy or chemotherapy and are eligible for surgical resection or biopsy to obtain a pathological diagnosis, or those highly suspected of having malignant pulmonary nodules according to clinical diagnostic criteria;
- Pathologically confirmed lung cancer via biopsy before neoadjuvant therapy; life expectancy ≥ 12 weeks;
- Ability to provide adequate tumor tissue for testing and research.
Exclusion criteria
- Women who are planning pregnancy, pregnant, or breastfeeding;
- History of other malignant tumors or prior receipt of other anti-tumor therapies;
- Poor or missing PET scan image quality of the probe that fails to meet analysis standards;
- Presence of claustrophobia or other mental illnesses;
- Any other conditions deemed by the investigators as inappropriate for participation in this study.
Where it is running
1 location listed.
- Peking University People's Hospital - Beijing, Beijing Municipality, China